Please assess the completion status of the following clinical trial:

Trial Title: An Open-label Study of KW-3357

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meet the ACCP/SCCM-defined sepsis criteria~* Japanese Association for Acute Medicine-defined DIC criteria score \>= 4~* Antithrombin activity \<= 70%~* Written informed consent from patient or guardian~Exclusion Criteria:~* Anamnesis or complication of serious drug allergy~* Serious liver disorder, such as fulminant hepatitis and decompensated cirrhosis~* Pregnant, nursing, or possibly pregnant woman

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KW-3357 (Type: EXPERIMENTAL): None
- Plasma-derived antithrombin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).